"I suffer from migraines. And I'm telling you, Nurtec is no joke. I took it and it made the pain stop. It made it go away. And that brought tears to my eyes."
Whoopi G.

Actual Nurtec ODT Patient.
Individual results may vary.

In a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), including patients with stable cardiovascular (CV) disease or CV risk factors1,2,4-6:

  • Co-primary endpoints at 2 h for Nurtec ODT vs placebo were pain freedom (21% vs 11%, P<.001) and freedom from most bothersome symptom (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%, P=.001).
  • Select secondary endpoints at 60 minutes for Nurtec ODT vs placebo were pain relief (37% vs 31%, P<.05) and return to normal function (22% vs 16%, P=.0025); from 2‑48 h for Nurtec ODT vs placebo were pain freedom (14% vs 5%, P<.001), return to normal function (26% vs 15%, P<.0001), and pain relief (42% vs 25%, P<.0001).
See full study design

Formulary coverage for your patients

More than 220 million insured individuals
have access to Nurtec ODT

Nurtec ODT is the exclusive oral CGRP receptor antagonist on Anthem's national commercial formulary.

Nurtec ODT is the exclusive oral CGRP receptor antagonist on the BlueCross BlueShield Federal Employee Program commercial formulary.

Nurtec ODT is the only preferred CGRP receptor antagonist on TRICARE's formulary.

Find coverage in your area.

Auto-locate

Error: Please provide a valid ZIP code.

OR

Error: Please provide a valid NPI number.

Error: Please provide either a ZIP code or an NPI number.

Managed Markets Insights & Technology LLC as of 02/21

Real Patients,
Real Stories

Patients are challenging what life with migraine can look
like with Nurtec ODT, one dose and one story at a time.

See patient stories

Actual Nurtec ODT Patient

Dr. Diamond discusses how Nurtec ODT can help address the unmet needs of adult patients suffering from migraine.

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Data on File. RIM108. Biohaven Pharmaceuticals, Inc. 4. Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: a phase 3, double-blind, randomized, placebo-controlled trial (study 303). Abstract presented at: 61st Annual Scientific Meeting of the American Headache Society; Philadelphia, PA. Session IOR05; July 11, 2019. 5. Data on File. RIM118. Biohaven Pharmaceuticals, Inc. 6. Data on File. RIM130. Biohaven Pharmaceuticals Inc.